Drug profile · INN
delavirdine mesylate
RESCRIPTOR
delavirdine mesylate (RESCRIPTOR) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — delavirdine mesylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
delavirdine mesylate (RESCRIPTOR) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Primary target: Human immunodeficiency virus type 1 reverse transcriptase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is delavirdine mesylate?
delavirdine mesylate (RESCRIPTOR) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for delavirdine mesylate?
RESCRIPTOR is a marketed brand name for delavirdine mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of delavirdine mesylate?
delavirdine mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.